Filing Flows › Castle Biosciences (CSTL) › Guidance history
Castle Biosciences (CSTL) guidance history: what it guided and what it reported
Castle Biosciences gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance 3 times and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $345M–$355M (May 6, 2026) → raised $365M–$375M (Jul 30, 2026) → raised $385M–$395M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Castle Biosciences beat its guidance?
Castle Biosciences gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance 3 times and lowered it 0 times.
How often does Castle Biosciences raise guidance?
Its earnings releases raised guidance 3 times and lowered it 0 times since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.